<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191231045958N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-12</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of locally administered Sambucus ebulus gel 5% on the severity and extention of pruritus in hemodialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of locally administered Sambucus ebulus gel 5% on the severity and extention of pruritus in hemodialysis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44648</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients were randomly assigned to each group using Permuted block Randomization as follows. We select 25 blocks of 6. The blocks will be from 120 different modes such as AABBCC, AABCBC, AACBCB, ABCABC, BABCAC, ACBBCA. In each block there will be two cases of group A and two cases of group B and two cases of group C. The computer program selects one randomly each time and the order of people in the groups is random, Blinding description: The person evaluating the severity of the itch is an unaware product.</study_design>
      <phase>2</phase>
      <hc_freetext>Pruritus in hemodialysis patients.</hc_freetext>
      <i_freetext>Intervention 1: The aim of this study was to investigate the effect of locally  administered  sambucus ebulus gel  5% on the severity and extention of  pruritus hemodialysis  patients.Three groups of patients are examined, in each group there are 50 hemodialysis patients. The first group uses sambucus ebulus 5%  gel - the second group uses placebo gel and the third group is without intervention. sambucus ebulus  gel prepared in the laboratory of Mazandaran University of Medical Sciences .After preparing the gel, Patients in both the intervention and placebo groups are taught to use the gel twice a day, morning and night, for 8 weeks.So as to cover the itchy area.Intervention group: Topical product containing 5% sambucus ebulus extract, twice daily for two months. Intervention 2: Control group: placebo gel. Fifty hemodialysis patients who are randomly assigned to this group use placebo gel prepared at the Faculty of Pharmacy, Mazandaran University. These patients are also taught to use the gel twice a day, morning and night, at home for 8 weeks to cover the itchy area. Intervention 3: Without intervention-This group was considered for the psychological dimension of drug use in patients with severe itching.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Patient data - Demographic information and itching score at each stage in each group

When:
Data will be available after the study and statistical analysis.

To whom:
There is no limit.

Conditions:
In order to conduct similar studies

Where to obtain:
Dr.Hedayat jafari

How to obtain:
0

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mohadese saberian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vesal street</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۶۷۱۵۷۹۳</zip>
        <telephone>۳۳۳۶۷۳۴۲</telephone>
        <email>h_saberian@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hedayat jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vesal street</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۶۷۱۵۷۹۳</zip>
        <telephone>۳۳۳۶۷۳۴۲</telephone>
        <email>Hedayat2003@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years who have been undergoing hemodialysis for more than 3 months
Patients who have had itching at least 3 times in the last 2 weeks
Despite drug use in the last month of treatment, no evidence of improvement was observed
Patients undergo hemodialysis 3 days a week for 3–5 hours per session
Have no skin problems other than uremic itching
Patients who gave their written consent to participate in the project
Patients who do not use another method to reduce the severity of itching
Lack of systemic diseases such as liver cholestatic, hepatitis B, HIV thyroid disorders and women who are not pregnant and breastfeeding
Lack of cognitive impairments that cannot answer questions</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>If the patient undergoes kidney transplantation during the study
If there is allergy to sambucus ebulus gel
Patients who do not wish to continue the study for personal reasons
Patients with a phosphorus test range of more than 6 and a PTH of more than 300</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L29.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pruritus, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The aim of this study was to investigate the effect of locally  administered  sambucus ebulus gel  5% on the severity and extention of  pruritus hemodialysis  patients.Three groups of patients are examined, in each group there are 50 hemodialysis patients. The first group uses sambucus ebulus 5%  gel - the second group uses placebo gel and the third group is without intervention. sambucus ebulus  gel prepared in the laboratory of Mazandaran University of Medical Sciences .After preparing the gel, Patients in both the intervention and placebo groups are taught to use the gel twice a day, morning and night, for 8 weeks.So as to cover the itchy area.Intervention group: Topical product containing 5% sambucus ebulus extract, twice daily for two months</i_keyword>
      <i_keyword>Control group: placebo gel. Fifty hemodialysis patients who are randomly assigned to this group use placebo gel prepared at the Faculty of Pharmacy, Mazandaran University. These patients are also taught to use the gel twice a day, morning and night, at home for 8 weeks to cover the itchy area.</i_keyword>
      <i_keyword>Without intervention-This group was considered for the psychological dimension of drug use in patients with severe itching.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pruritus. Timepoint: first visit-The fourth and eighth week after starting to use the gel. Method of measurement: 48-point scale for itching severity.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Skin dryness. Timepoint: first week, The fourth and eighth week after starting to use the gel. Method of measurement: Examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-03-11</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Moalem Square Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
